Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Labeling Request Memorandum, May 14, 2012 - MenHibrix

Date: May 14, 2012

To: 125363
From: David Staten, RPM

Subject: Labeling Request

Reference is made to the Hiberix (STN 125347) file to include a 0.9% sodium chloride diluent vial presentation manufactured by –b(4)-------------------. Changes had been made in the PI for this supplement that will pertain equally to the MenHibrix PI. In order to facilitate the review of the MenHibrix labeling, CBER requested a revised PI which contains the changes made to the Hiberix PI. GSK agreed.

Page Last Updated: 07/15/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English